FTC staff recommends approval of Roche deal for Spark: report

FTC staff recommends approval of Roche deal for Spark: reportThe Federal Trade Commission staff reviewing Roche’s plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $ 4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday. Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the U.S. company, acquiring a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for neurodegenerative disorders like Huntington’s disease. One of its projects is a gene therapy treatment for hemophilia.



Yahoo Finance

You may also like...